Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Editas Medicine (EDIT) Income from Continuing Operations (2016 - 2025)

Editas Medicine (EDIT) has disclosed Income from Continuing Operations for 11 consecutive years, with 25116000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations rose 59.58% to 25116000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 197648000.0, a 6.13% increase, with the full-year FY2024 number at 237090000.0, down 56.38% from a year prior.
  • Income from Continuing Operations was 25116000.0 for Q3 2025 at Editas Medicine, up from 51477000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 18861000.0 in Q4 2023 to a low of 75663000.0 in Q1 2025.
  • A 5-year average of 50206894.74 and a median of 51477000.0 in 2025 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: tumbled 524.37% in 2021, then skyrocketed 68.94% in 2023.
  • Editas Medicine's Income from Continuing Operations stood at 41435000.0 in 2021, then crashed by 46.58% to 60734000.0 in 2022, then surged by 68.94% to 18861000.0 in 2023, then crashed by 140.67% to 45392000.0 in 2024, then surged by 44.67% to 25116000.0 in 2025.
  • Per Business Quant, the three most recent readings for EDIT's Income from Continuing Operations are 25116000.0 (Q3 2025), 51477000.0 (Q2 2025), and 75663000.0 (Q1 2025).